# US 2004/0001805 A1 · Method and compositions for conferring viral immunity and reversing viral pathogenesis via strategic infection with a theravirus thereby providing genomic integration of genetically engineered, replication incompetent, integrating viral DNA

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0001805 A1
- Document ID: US20040001805A1
- Status: Published application
- Kind: A1
- Application number: 10/298,997
- Filed: 2002-11-19
- Published: 2004-01-01
- Earliest claimed: 2001-11-19
- Inventors: Lawrence F. Glaser
- Web page: https://patentgrep.com/patent/US20040001805A1

## CPC

- A61K 39/12: Viral antigens
- A61K 2039/5254: {avirulent or attenuated}
- C12N 2710/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides a method of conferring viral immunity and/or reversing viral pathogenesis via strategic genomic integration of a genetically engineered replication incompetent vDNA composition, i.e., a theravirus. The invention is generally effectuated by administering to a host a therapeutic amount of genetically engineered viral DNA (vDNA) composition in an amount sufficient to out-compete the natural pathogenic vDNA's ability to integrate into the host cells genome. The genetically engineered vDNA construct is genetically altered in a manner that effectively prevents post integration transcription of the composition. The invention is effective in the prevention and treatment of viral infections, including, HIV (AIDS), herpes and hepatitis.

## Claims

### Claim 1

A method of treating or preventing viral infection or viral proliferation caused by virus insertion of a wild-type viral genome, as integrated vDNA, into a host cell chromosome comprising the step of administering to a host a therapeutically effective titre of a viral genome containing genomic regions needed for transport in the cell, infection and any subsequent transport into a cell nucleus wherein those genomic regions of the viral genome not needed for transport into the cell, infection and subsequent transport into a cell nucleus are rendered inactive.

### Claim 2

A method of maintaining a reduced wild-type viral load in a host cell, which has been treated with a viral genome containing genomic regions needed for transport in the cell, infection and any subsequent transport into a cell nucleus wherein those genomic regions of the viral genome not needed for transport into the cell, infection and any subsequent transport into a cell nucleus are rendered inactive, comprising the steps of
periodically extracting wild-type virions from the treated host cell,
determining whether the extracted wild-type virions have a genome that has either mutated or recombined with the viral genome to render the viral genome ineffective for treating or prevention viral infection, and, when determined to have rendered the viral genome ineffective,
preparing another viral genome from the extracted wild-type virion vDNA wherein the another viral genome contains the genomic regions needed for transport into the cell, infection and any subsequent transport into a cell nucleus while those genomic regions not needed for transport into the cell, infection and any subsequent transport into a cell nucleus are disabled, and
administering to the treated host a therapeutically effective titre of the another viral genome containing genomic regions needed for transport into the cell, infection and any subsequent transport into a cell nucleus wherein those genomic regions in the another viral genome not needed for transport into the cell, infection and any subsequent transport into a cell nucleus are rendered inactive.

### Claim 3

A cell line for producing virions containing a viral genome containing the genomic regions needed for transport into a host cell, infection and any subsequent transport into a host cell nucleus wherein those genomic regions of the viral genome not needed for transport into the host cell, infection and any subsequent transport into a host cell nucleus are rendered inactive.

### Claim 4

A supernatant comprising virion particles containing a viral genome containing the genomic regions needed for transport into a host cell, infection and any subsequent transport into a host cell nucleus wherein those genomic regions of the viral genome not needed for transport into the host cell, infection and any subsequent transport into a host cell nucleus are rendered inactive.

### Claim 5

A vaccine comprising virions containing a viral genome containing the genomic regions needed for transport into a host cell, infection and any subsequent transport into a host cell nucleus wherein those genomic regions of the viral genome not needed for transport into the host cell, infection and any subsequent transport into a host cell nucleus are rendered inactive.
